Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up.

J Oral Maxillofac Surg. 1996 May;54(5):583-7; discussion 588-9. Unique Identifier : AIDSLINE MED/96209026
McCormick SU; New York Eye and Ear Infirmary, New York 10003, USA.

Abstract: PURPOSE: This study evaluated the use of intralesional vinblastine injections for the treatment of the intraoral lesions of Kaposi's sarcoma. PATIENTS AND METHODS: Eighteen patients were treated with up to three intralesional injections of 0.1 mg/cc vinblastine. RESULTS: All lesions responded to the local injections; 40% required one injection; 31%, two injections; and 29%, three injections. Large, exophytic lesions usually required the multiple injections. No complications were encountered, and the patients tolerated the protocol well. Ten patients were followed for 24 months. Eight died of their general disease during this period. Four patients developed new intraoral lesions, which were treated with, and responded favorably to, the three-injection protocol. CONCLUSION: Intralesional vinblastine injections are an effective and useful treatment alternative for human immunodeficiency virus (HIV)-associated intraoral Kaposi's sarcoma.
Keywords: Antineoplastic Agents, Phytogenic/ADMINISTRATION & DOSAGE/ *THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY Follow-Up Studies Gingival Neoplasms/DRUG THERAPY Human HIV Seropositivity Injections, Intralesional Mouth Neoplasms/*DRUG THERAPY Neoplasm Recurrence, Local/PATHOLOGY Palatal Neoplasms/DRUG THERAPY Remission Induction Sarcoma, Kaposi's/*DRUG THERAPY Tongue Neoplasms/DRUG THERAPY Vinblastine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE JOURNAL ARTICLEKWDantineoplasticagents,phytogenic/administration&dosage/KWDtherapeuticuseaids-relatedopportunisticinfections/drugtherapyfollow-upstudiesgingivalneoplasms/drugtherapyhumanhivseropositivityinjections,intralesionalmouthneoplasms/KWDdrugtherapyneoplasmrecurrence,local/pathologypalatalneoplasms/drugtherapyremissioninductionsarcoma,kaposi's/KWDdrugtherapytongueneoplasms/drugtherapyvinblastine/administration&dosage/KWDtherapeuticusejournalarticle
960930
M9690905

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .